We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
-5.08%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$4.82B
AUM Growth
-$690M
Cap. Flow
-$124M
Cap. Flow %
-2.58%
Top 10 Hldgs %
17.51%
Holding
1,588
New
254
Increased
693
Reduced
409
Closed
141

Top Buys

Rank Stock Value
1
DIDI
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
+$50.6M
2
CAT icon
Caterpillar
CAT
+$27M
3
ADI icon
Analog Devices
ADI
+$22.8M
4
CSX icon
CSX Corp
CSX
+$20.1M
5
PTY icon
PIMCO Corporate & Income Opportunity Fund
PTY
+$15M

Top Sells

Rank Stock Value
1
BIDU icon
Baidu
BIDU
+$24.6M
2
BCX icon
BlackRock Resources & Commodities Strategy Trust
BCX
+$22.3M
3
MXIM
Maxim Integrated Products
MXIM
+$21.2M
4
NFJ
Virtus Dividend, Interest & Premium Strategy Fund
NFJ
+$21.1M
5
VVR icon
Invesco Senior Income Trust
VVR
+$19.6M

Sector Composition

Rank Sector Weight
1 Technology 27.8%
2 Consumer Discretionary 25.32%
3 Communication Services 11.6%
4 Industrials 6.01%
5 Financials 5.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
1401
DELISTED
Inozyme Pharma
INZY
$6K ﹤0.01%
540
+5
+0.9% +$78
PBYI icon
1402
Puma Biotechnology
PBYI
$454M
$6K ﹤0.01%
930
+10
+1% +$75
SYRS
1403
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6K ﹤0.01%
142
+1
+0.7% +$49
ACET icon
1404
Adicet Bio
ACET
$74.7M
$5K ﹤0.01%
46
+1
+2% +$124
CLLS
1405
Cellectis
CLLS
$285M
$5K ﹤0.01%
475
+45
+10% +$623
IMUX icon
1406
Immunic
IMUX
$195M
$5K ﹤0.01%
60
+10
+20% +$984
KMDA icon
1407
Kamada
KMDA
$419M
$5K ﹤0.01%
1,025
+5
+0.5% +$27
KRRO icon
1408
Korro Bio
KRRO
$195M
$5K ﹤0.01%
16
– –
OVID icon
1409
Ovid Therapeutics
OVID
$491M
$5K ﹤0.01%
1,555
+10
+0.6% +$36
WVE icon
1410
Wave Life Sciences
WVE
$1.2B
$5K ﹤0.01%
1,165
+30
+3% +$182
TECX
1411
Tectonic Therapeutic
TECX
$606M
$5K ﹤0.01%
83
+4
+5% +$328
EIGR
1412
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5K ﹤0.01%
26
– –
GMDA
1413
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$5K ﹤0.01%
1,350
– –
CBAY
1414
DELISTED
Cymabay Therapeutics
CBAY
$5K ﹤0.01%
1,580
+10
+0.6% +$39
PRTK
1415
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5K ﹤0.01%
1,110
+40
+4% +$220
HARP
1416
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$5K ﹤0.01%
75
+1
+1% +$101
TCDA
1417
DELISTED
Tricida, Inc. Common Stock
TCDA
$5K ﹤0.01%
1,155
+10
+0.9% +$41
KLDO
1418
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$5K ﹤0.01%
970
– –
ADVM
1419
DELISTED
Adverum Biotechnologies
ADVM
$4K ﹤0.01%
225
+2
+0.9% +$51
LRMR icon
1420
Larimar Therapeutics
LRMR
$432M
$4K ﹤0.01%
405
+55
+16% +$660
MNOV icon
1421
MediciNova
MNOV
$66M
$4K ﹤0.01%
1,120
+10
+0.9% +$38
NXTC icon
1422
NextCure
NXTC
$26.7M
$4K ﹤0.01%
53
– –
RDHL
1423
Redhill Biopharma
RDHL
$3.68M
$4K ﹤0.01%
1
– –
BCEL
1424
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4K ﹤0.01%
690
+5
+0.7% +$33
RVLP
1425
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$4K ﹤0.01%
1,440
+10
+0.7% +$34
55 56
57
58 59

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Penserra Capital Management held 1,588 positions worth $4.82B, down 13% from $5.51B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Penserra Capital Management's Q3 2021 filing shows 254 new, 693 increased, 409 reduced and 141 closed positions. Its largest new stake was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 5,364,893 shares worth $41.8M. The largest sale was Baidu, an estimated $24.6M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • Penserra Capital Management's largest Q3 2021 buy was DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share: 5,364,893 shares worth $41.8M.
  • Penserra Capital Management added most to Analog Devices in Q3 2021, an estimated $22.8M increase.
  • Penserra Capital Management's biggest Q3 2021 reduction was Baidu, cutting an estimated $24.6M.
  • Penserra Capital Management fully exited BlackRock Resources & Commodities Strategy Trust in Q3 2021, selling an estimated $22.3M.
  • Penserra Capital Management's ten largest holdings make up 18% of its $4.82B portfolio in Q3 2021.
  • Penserra Capital Management opened 254 new positions and closed 141 in Q3 2021.
  • Penserra Capital Management's portfolio value fell 13% quarter-over-quarter to $4.82B.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.